Home LiteratureArticle Details
PMID: 15983262 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Review

Pathophysiology of coronary artery disease.

Circulation ·Vol. 111 ·No. 25 ·2005-06-28 ·Pages 3481-8

Libby P, Theroux P

Abstract

During the past decade, our understanding of the pathophysiology of coronary artery disease (CAD) has undergone a remarkable evolution. We review here how these advances have altered our concepts of and clinical approaches to both the chronic and acute phases of CAD. Previously considered a cholesterol storage disease, we currently view atherosclerosis as an inflammatory disorder. The appreciation of arterial remodeling (compensatory enlargement) has expanded attention beyond stenoses evident by angiography to encompass the biology of nonstenotic plaques. Revascularization effectively relieves ischemia, but we now recognize the need to attend to nonobstructive lesions as well. Aggressive management of modifiable risk factors reduces cardiovascular events and should accompany appropriate revascularization. We now recognize that disruption of plaques that may not produce critical stenoses causes many acute coronary syndromes (ACS). The disrupted plaque represents a "solid-state" stimulus to thrombosis. Alterations in circulating prothrombotic or antifibrinolytic mediators in the "fluid phase" of the blood can also predispose toward ACS. Recent results have established the multiplicity of "high-risk" plaques and the widespread nature of inflammation in patients prone to develop ACS. These findings challenge our traditional view of coronary atherosclerosis as a segmental or localized disease. Thus, treatment of ACS should involve 2 overlapping phases: first, addressing the culprit lesion, and second, aiming at rapid "stabilization" of other plaques that may produce recurrent events. The concept of "interventional cardiology" must expand beyond mechanical revascularization to embrace preventive interventions that forestall future events.

MeSH Terms
Constriction, Pathologic Coronary Artery Disease/etiology,pathology,therapy Coronary Thrombosis Humans Inflammation Secondary Prevention
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Libby Peter
Donald W. Reynolds Cardiovascular Clinical Research Center, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115, USA. plibby@rics.bwh.harvard.edu
Theroux Pierre
Article Info
Journal
Circulation
Abbr.
Circulation
ISSN
1524-4539
Published
2005-06-28
Pages
3481-8
Language
English
Region
United States
NLM ID
0147763
Subset
IM
Grants
NHLBI NIH HHS · HL-34636 · United States
NHLBI NIH HHS · HL-48743 · United States
NHLBI NIH HHS · HL-56985 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com